NAT2基因多态性与柳氮磺吡啶治疗溃疡性结肠炎安全性的关系  

NAT2 Genotype-related Security of Sulfasalazine in Treatment of Ulcerative Colitis

作　　者：孟珺[1] 刘丽娟[1] 刘玉琴[1] 陈小英[1] 白瑶[1] 何光明[1] 

机构地区：[1]北京大学深圳医院药剂科,广东深圳518036

出　　处：《中国药师》2009年第8期1008-1010,共3页China Pharmacist

基　　金：深圳市科技局基金资助项目(编号200703219)

摘　　要：目的:探讨N-乙酰基转移酶2(NAT2)基因型多态性与柳氮磺吡啶(SASP)治疗溃疡性结肠炎(UC)安全性的关系。方法:在38例UC患者及36例健康对照者中,采用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)法检测NAT2的基因多态型,并对UC患者进行NAT2基因型与SASP药物不良反应(ADR)的相关性分析。结果:慢型乙酰化基因型的UC患者服用SASP后ADR的发生率高于快型乙酰化基因型患者,差异有统计学意义(P<0.01)。结论:UC患者使用SASP出现的ADR与NAT2慢型乙酰化基因型相关。Objective： To investigate the association between N-acetyltransferase 2 （ NAT2 ） genotypes and security of sulfasalazine in treatment of ulcerative colitis （ UC ）. Method： Thirty eight patients with UC and 36 controls were recruited in this study. The NAT2 genotype poly-morphisms were determined by the polymerase chain reaction restriction fragment length polymorphism method. The association between NAT2 genogtypes and security of sulfasalazine was analyzed. Result： The slow acetylators had more adverse drug reactions than the rapid acetylators （p 〈 0.01 ）. Conclusion： Slow acetyator genotype is related to the adverse drug reactions of sulfasalazine.

关 键 词：NAT2 基因型 柳氮磺吡啶 溃疡性结肠炎 

分 类 号：R968[医药卫生—药理学]